Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors
Last oncolytics biotech, inc earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com
Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this modelPelareorep's synergistic effects with CAR T therapy appear to be specific and were not observed with the oncolytic virus VSVResults demonstrate the potential of pelareorep to broaden the applicability of CAR T cells to solid tumors SAN DIEGO, Calif. and CALGARY, AB, Feb. 23, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced publication of an electronic poster at the CAR-TCR Summit Europe 2021 with data from a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors.Newly published results show that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model, in stark contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. Efficacy of pelareorep-loaded CAR T ce
[Read more]
| Impact snapshot | Event time: | ONCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ONCY alerts
ONCY alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech, Inc news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Oncolytics Biotech Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ONCY/price-target/">NASDAQ: ONCY</a>) had its "speculative buy" rating re-affirmed by analysts at Leede Jones Gab.MarketBeat
- Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational HighlightsPR Newswire
- Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer TherapiesPR Newswire
- Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of CancerPR Newswire
- Oncolytics Biotech Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ONCY/price-target/">NASDAQ: ONCY</a>) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- More
ONCY
SEC Filings
- 2/26/21 - Form 6-K
- 2/23/21 - Form 6-K
- 12/9/20 - Form 6-K
- ONCY's page on the SEC website
- More